Zhongxin Finance, May 18 (Reporter Xie Yiguan) If you talk about what is the most popular recently, "Qianjintansu" is on the list. Before, the listed companies in the traditional Chinese medicine category were "in touch" and rose. Now this "fire" is still burning traditional Chinese medicine. material market.

One price per day

  "The price of Qianjin vine has changed rapidly in recent days." On the 17th, a relevant person in charge of a medicinal material sales company in Bozhou, Anhui told a reporter from Zhongxin Finance and Economics.

  "On the 13th and 14th, before the fire started, the highest retail price of Qianjin rattan was 60 yuan per kilogram, and there were also 20 to 30 yuan per kilogram." The person in charge said, "Today (17th) Goods (from 100 kilograms) have been sold for 110 yuan a kilogram, and retail sales have reached 160 yuan a kilogram."

  According to the person in charge, recently, many old customers are also asking about vines. Some people want to buy them for home cooking, and there are pharmaceutical factories to extract them. Some clinics and hospitals are also asking for vines.

  Taking into account the demand for this period of time, the person in charge predicted that the price may continue to rise in the future.

  According to media reports, it was learned from relevant persons of Kangmei Traditional Chinese Medicine Network that the price of Chinese herbal medicine Qianjinteng has increased significantly recently. The market price has risen from 10 yuan per kilogram to more than 25 yuan per kilogram, and some drug dealers have quoted as high as 65 yuan/kg. Kilogram.

  A reporter from China-News Finance and Economics noticed that there have been a number of pieces of information about the acquisition of Qianjinteng on some social media recently.

Many people said, "A large number of acquisitions can be delivered to your door."

Why did Qianjinvine suddenly explode?

  According to public information, Radix chinensis is a traditional Chinese medicine in my country, which belongs to the fangchi family and genus Radix chinensis.

It is an alkaloid isolated and extracted from the tubers or vines of the genus A. chinensis, and it is an active ingredient of Chinese herbal medicine. It has been approved for the treatment of many diseases.

  Previously, fenugreek was mostly used as analgesics and leukocyte proliferation drugs, which can promote the proliferation of bone marrow tissue, thereby increasing white blood cells.

  The recent explosion of Qianjinteng stemmed from a piece of news: on May 10, a new drug for the treatment of new crowns discovered by Chinese scientists was authorized by the national invention patent.

The patent specification shows that 10 μM (micromol/L) of fenugreek inhibits the replication of coronavirus by 15,393 times.

Screenshot from the official website of the State Intellectual Property Office.

  Tong Yigang, dean of the School of Life Science and Technology, Beijing University of Chemical Technology, the inventor of the patent, said that from the current research data, the drug's ability to inhibit the new coronavirus ranks high among all the new coronavirus inhibitors discovered by humans.

  This is not the first time that fenugreek has appeared in the public eye due to its super anti-coronavirus activity.

As early as February 2020, fenugreek was found by Tong Yigang's team to be effective in inhibiting the new coronavirus.

  "The report on Qianjin Phengsu was published more than two years ago, and there was no response at that time. I didn't expect that the report on this patent would attract so much attention, which may be related to the current epidemic situation." Tong Yigang said in a meeting on the afternoon of the 16th. Emphasized in the live broadcast.

Concept stocks soared, and many companies were busy clarifying

  What Tong Yigang did not expect was that this report also caused a skyrocketing rise in related traditional Chinese medicine stocks.

  On May 13, the stocks of some listed Chinese medicine companies began to "take off", Qianjin Pharmaceutical, Bio Valley, etc. had daily limit, and Yunnan Baiyao rose sharply.

On May 16, after the fermentation of news related to "Qianjin Tensu" over the weekend, the stock prices of traditional Chinese medicine companies soared. .

  However, according to the official website of the State Food and Drug Administration, there are only four domestic companies that have approval documents for Qianjintiansu tablets, namely Shenyang Guancheng Pharmaceutical, Yunnan Baiyao Group Wenshan Qihua Company, Yunnan Baiyao Group Dali Pharmaceutical and Yunnan Bio Valley Pharmaceutical.

Screenshot from the official website of the State Food and Drug Administration.

  Therefore, among these soaring stocks with "Qianjintiansu", only Bio Valley and Yunnan Baiyao do have the approval of Qianjintiansu, and many others have no related business.

Dali Pharmaceutical even collided with the name of Yunnan Baiyao Group Dali Pharmaceutical, and Qianjin Pharmaceutical only had the word "Qianjin" in its name, and the stocks were both "Er Lianban".

  In the face of soaring stock prices, listed companies such as Qianjin Pharmaceutical, North China Pharmaceutical, and Buchang Pharmaceutical have successively issued clarification announcements, and some listed companies have also responded to related questions through interactive platforms.

  As companies have "clarified" one after another, on May 17, the performance of Qianjintansu concept stocks in the capital market diverged.

Dali Pharmaceuticals fell by the limit, Qianjin Pharmaceuticals and Youningwei also fell, and the shares of Bio Valley and Fangsheng Pharmaceuticals continued to rise.

Dali Pharmaceutical's daily K chart.

  However, some brokerage research reports still believe that under the current epidemic fermentation and the unique market environment, the attention of the new crown theme is very high, and the new crown theme that cannot be falsified in the short term at this time is worthy of attention.

  However, since there are still many steps to be taken from the advent of related drugs, many people questioned that this time Qianjinsu was a "false fire".

  Recently, Tong Yigang also said in an interview with the media, "I also hope that this drug will complete animal experiments and clinical research as soon as possible. But the main problem is that this drug is not available in China, so it must be made first." (End)